Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report released on Tuesday morning,Benzinga reports. They currently have a $18.00 price objective on the stock.

Separately, Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday, February 6th.

Coya Therapeutics Stock Down 5.8 %

Shares of COYA stock opened at $6.45 on Tuesday. The firm has a market cap of $107.76 million, a P/E ratio of -9.92 and a beta of 0.31. The company has a 50 day moving average of $6.30 and a 200-day moving average of $6.49. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.42.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.14. The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.10 million. As a group, equities analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in COYA. Tower Research Capital LLC TRC raised its position in Coya Therapeutics by 1,005.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after purchasing an additional 4,777 shares in the last quarter. XTX Topco Ltd purchased a new position in shares of Coya Therapeutics during the 4th quarter valued at about $59,000. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics during the 4th quarter valued at about $74,000. Northern Trust Corp lifted its position in Coya Therapeutics by 12.2% in the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company’s stock worth $164,000 after buying an additional 3,099 shares during the last quarter. Finally, Newbridge Financial Services Group Inc. purchased a new stake in Coya Therapeutics in the fourth quarter worth approximately $401,000. 39.75% of the stock is currently owned by hedge funds and other institutional investors.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.